Use of soluble myeloid cell-surface glycoprotein in the treatment or prevention of chronic inflammatory conditions and clinical disorders of insulin resistance e.g. type 2 diabetes and obesity

摘要

In the manufacture of a medicament for treatment or prevention of chronic inflammatory conditions and clinical disorders associated with insulin resistance in an animal or human, soluble myeloid cell-surface glycoprotein (soluble CD14 (sCD14)) is used. ACTIVITY : Antiinflammatory; Antidiabetic; Anorectic; Antiarteriosclerotic; Hypotensive; Antilipemic. C57BL/6J ob/ob Male mice having obesity with hyperphagia, hyperinsulinemia, insulin resistance and moderate hyperglycemia were infused by recombinant myeloid cell-surface glycoprotein (rhCD14) (test) for 12 days by using Alzet (RTM; pump) implanted subcutaneously. Another group of mice (control) was administered with saline serum subcutaneously at a dosage of 1 Microg/g. After 16 hours of fasting, intraperitoneal glucose tolerance test (GTT) was carried out. Glucose (2 g/kg) was injected intraperitoneally. Blood samples (20 Microl) were taken from tail of mice at 0, 15, 30, 60, 120 and 180 minutes after glucose administration and blood glucose level was measured. It was observed that test treated mice showed decreased basal levels of serum glucose as compared to the control. The fasting blood glucose level for test/control was 153+-14/242+-30 mg/dL. The concentration of serum insulin also decreased concomitantly with the decrease in serum glucose in test treated mice. The results showed that the test had positive effect on normalization of blood glucose level and hence showed improved insulin sensitivity as compared to the control. MECHANISM OF ACTION : Lipopolysaccharide blocker.